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Background
Small bowel adenocarcinoma is a rare cancer and consequently the options for clinical trials are limited. As they are treated according to either a colorectal or a gastric cancer regimen and the molecular biology of a tumor is a pivotal determinant for therapy response, chromosomal copy number aberrations were compared with the colorectal and gastric adenocarcinomas.
Materials and methods
A total of 85 microsatellite stable (MSS) adenocarcinomas from the stomach, colorectum and small bowel were selected from existing comparative genomic hybridization (aCGH) datasets. We compared the aCGH pro les of the three tumor sites by supervised analysis and hierarchical clustering.
Results
Hierarchical clustering revealed substantial overlap of 27 small bowel adenocarcinoma copy number pro les with matched colorectal adenocarcinomas, but less overlap with pro les of gastric adenocarcinomas. DNA copy number aberrations located at chromosomes 1p36.3-p34.3, 4p15.3-q35.2, 9p24.3-p11.1, 13q13.2-q31.3 and 17p13.3-p13.2 were the strongest features discriminating small bowel and colorectal adenocarcinomas from gastric adenocarcinomas.
Conclusions
We show that MSS small bowel adenocarcinomas are more similar to colorectal than to gastric cancer, based on the 27 genome-wide DNA copy number pro les that are currently available. These molecular similarities provide added support for treatment of MSS small bowel cancers according to colorectal cancer regimens.
INTRODUCTION
Small bowel adenocarcinomas are rare and comprise only about 2% of gastrointestinal malignancies. 1, 2 Prognosis of patients with small bowel adenocarcinomas is poor with a ve year overall survival rate of 20 to 30%. 3 Small bowel adenocarcinomas are usually diagnosed at an advanced stage requiring systemic drug therapy in addition to surgical resection. Clinical trials to determine optimal treatment regimens for patients with small bowel adenocarcinomas have been limited due to the low incidence. As a result, patients with small bowel adenocarcinomas are treated with either colorectal or gastric cancer drug regimens. 2, 4 The molecular biology of a tumor is a pivotal determinant for therapy response, implying that common molecular characteristics lead to comparable drug sensitivity. Relations in the molecular biological between small bowel adenocarcinomas on the one hand and colorectal and gastric cancer on the other, could therefore aid in therapy selection.
Associations of response to systemic chemotherapy with molecular characteristics are ample, however limited for a relatively new technique such as aCGH. [5] [6] [7] [8] One genomewide study demonstrates that a deletion of chromosome 11q is correlated with a better response to anthracycline-based chemotherapy in early breast cancer. 8 In another study we demonstrated that colorectal cancer patients who do respond to systemic combination therapy with capecitabine and irinotecan have regions located on chromosome 18 frequently deleted. 6 Speci c gene ampli cations, such as N-myc, EGFR and ERBB2, are decisive factors in therapy choice. 5 Copy number aberrations are frequently referred to as a hallmark of cancer. Indeed, by analyzing DNA copy number pro les of 373 cancers we demonstrated, that cancers cluster according to their embryological origin. 9 Others have shown that tumor subtypes that are based on copy number can have different prognosis. 10 Thus, although currently limited precedent exits for genome-wide copy number pro les in relation to therapy, copy numbers well represent the biology of a tumor.
Since aCGH can be performed using DNA extracted from formalin xed paraf n embedded (FFPE) archival tissue 11 it is feasible to create series of rare tumors such as small bowel adenocarcinomas. The aim of our current study was to investigate whether small bowel adenocarcinomas copy number pro les are more similar to those of colorectal or gastric adenocarcinomas. The result of such a comparison may provide further insights into the biology of small bowel adenocarcinomas and establish some evidence for choosing the optimal treatment regimen for these patients.
MATERIALS & METHODS
Data collection
The series of samples in the present study was composed of three previously published series. [12] [13] [14] [15] [16] In these studies two different aCGH platforms were used; 5K BAC arrays 17 and 30K oligonucleotide arrays.
18 All data were generated using DNA isolated from FFPE tumor tissues and had more than 70% tumor cells. Obviously, the number of available small bowel adenocarcinoma samples that could be included was the rate limiting factor.
Microsatellite instable adenocarcinomas were excluded, since these represent a different biological entity. 19 The 27 microsatellite stable samples 14 were matched with gastric and colorectal adenocarcinomas based on TNM stage, 20 gender and age. If multiple samples matched equally well, one sample was randomly selected (supplementary Table1).
Gastric adenocarcinomas were selected from a set of 206 samples analyzed with BAC aCGH (Buffart et al., submitted for publication) including 122 randomly selected samples from the Dutch D1/D2 trial 15 and 84 randomly selected samples from the archives of the University of Leeds (Leeds, general In rmary,UK). Of these samples 139 were microsatellite stable all of intestinal type.
Colorectal adenocarcinomas were selected from an initial aCGH dataset of a panel of 74 colorectal tumors, performed on BAC aCGH. 12 Of these 74 colorectal adenocarcinomas, 64 are microsatellite stable. All aCGH data are publicly available under accession number GSE23418 (http://www.ncbi.nlm.nih.gov/geo/ and supplementary Table1).
Cross-platform calibration
Since the original DNA copy number pro les were generated using two different aCGH platforms, prior to clustering and classi cation, resolution and de ection differences of the copy number pro les were calibrated. To facilitate the calibration procedures, two small bowel, two gastric and two colorectal adenocarcinomas were analyzed on both the BAC and oligonucleotide aCGH platform. The results from this experiment were used to establish the required preprocessing steps in order to obtain platform independent pro les and copy number calls. Preprocessing methods as well as meta-analysis procedures were performed using R, version 2.6.1. Processing procedures are described in supplementary Materials and Methods. The success of the platform calibration was assessed by hierarchical clustering of the six samples, which showed that the same samples clustered in pairs independent of the aCGH platform (supplementary Figure 1) . For clustering the R package WECCA, 21 designed for clustering copy number pro les rather than expression pro les, was used with probabilities as described by Smeets et al. 22 with settings: "ordinal", "all equal" and "ward linkage".
Meta-analysis procedures
The entire dataset was preprocessed, normalized and calibrated as described for the calibration samples. DNA copy number data was determined by "CGHcall", calling probabilities of 0.5 or more. The accuracy of the normalization, segmentation and calling was veri ed by visual inspection. Regions of gains and losses were used for the supervised and unsupervised analysis. 23 For supervised analysis a two-sample Wilcoxon test using 10.000 permutations was performed to calculate the signi cance of DNA copy number differences between small bowel and gastric adenocarcinomas and between small bowel and colorectal adenocarcinomas for each region. 24 Two separate tests were performed to compare frequencies of gains and frequencies of losses between the groups. P-values were corrected for multiple testing using permutation-based false discovery rate (FDR). Regions with FDR < 0.05 were taken into account to calculate the difference in number of regions and length of the genome between small bowel and gastric adenocarcinomas and between small bowel and colorectal adenocarcinomas. Similarities between small bowel and gastric adenocarcinomas and between small bowel and colorectal adenocarcinomas were de ned by the overlap of aberrant regions occurring in more than 33% per organ of origin as previously described. 25 Additionally to determine similarities between small bowel and colorectal and between small bowel and gastric adenocarcinomas a Pearson correlation was calculated based on the frequencies of the gains and losses of the regions. Per region the maximum frequency of either loss or gain was calculated. The frequencies of losses were multiplied by -1.
Unsupervised clustering was performed as described for the control samples. To determine the number of most stable clusters, consensus clustering 26 was implemented. The stability of 2-5 clusters was measured by running the clustering 1000 times leaving out 20% of the samples each time.
To evaluate whether the samples cluster by site of origin the chi-square test was used. To nd the most discriminative features between clusters the distance between all regions was de ned as the symmetric Kullback-Leibler divergence. 27 To obtain the list of UCSC genes located on the most discrimination regions the UCSC table browser data retrieval tool was used. 28 Genes overlapping with the Cancer Census 29 list were identi ed (Table1).
RESULTS
Frequency of DNA copy number aberrations in selected gastrointestinal adenocarcinomas
The overall pattern of DNA copy number changes in microsatellite stable adenocarcinomas of the small bowel, stomach and colorectum found in the current study are consistent with frequencies of deletions and gains reported in literature ( Figure 1 ). Most common aberrant regions in colorectal adenocarcinomas were gains of chromosomes 7, 8q, 13, and 20q and losses of chromosomes 4, 8p, 14, 15, 17p and 18. 30, 31 Most common aberrant regions in small bowel adenocarcinomas were gains of chromosomes 5p, 7, 8q, 13, 16 and 20 and losses of chromosomes 4, 5q, 8p, 17p, and 18. 32, 33 Most common aberrant regions in gastric adenocarcinomas were gains of chromosomes 1p, 7p, 8q, 17q, 20 and losses of chromosomes 3p, 4, 5q, 6q, 9p, 12q, 13 and 18q. 31, [34] [35] [36] Thus, the selected sets of samples from each tumour site were considered to be representative.
Differences and similarities between gastrointestinal adenocarcinomas by supervised analyses
Signi cant differences as well as similarities are observed between the three tumor sites (Figure 1 ). Similarities were determined by the overlap of the genome that was aberrant in more than 33% of the tumors per site. Copy number aberrations that were observed in more than 33% of the 27 small bowel adenocarcinomas encompassed 32% of the genome. Similarly, 30% and 36% of the genome was aberrant with frequencies of gains or losses higher than 33% in colorectal and gastric adenocarcinomas, respectively. Sixty-four percent of these aberrant regions in small bowel adenocarcinomas were also aberrant in These results indicate that the DNA copy number aberrations might be organ-speci c and that small bowel adenocarcinomas are molecularly more similar to colorectal than to gastric adenocarcinomas. Differences between small bowel versus gastric adenocarcinomas and small bowel versus colorectal adenocarcinomas might be somewhat skewed due to platform differences.
Unsupervised hierarchical clustering of gastrointestinal adenocarcinomas
Unsupervised hierarchical cluster analysis of colorectal and gastric adenocarcinomas revealed two distinct clusters (Figure 2a ): one containing primarily gastric adenocarcinomas (n=24) and only 2 colorectal adenocarcinomas, the other one containing primarily colorectal adenocarcinomas (n=27) and only 5 gastric adenocarcinomas (p-value <0.001). In addition, we identi ed that this dataset consist of 2 stable clusters by consensus clustering 26 (data not shown), con rming that these two clusters are robust. In either the comparison of small bowel to gastric or colorectal adenocarcinomas results cannot be in uenced by platform differences since both gastric and colorectal adenocarcinomas were performed on the same platform and only small bowel adenocarcinomas were different. and more frequently lost in "GC cluster"
17p13.3-p13.2 USP6 More frequently lost in "CRC cluster"
DISCUSSION
Our study demonstrates that small bowel adenocarcinomas are more like colorectal than gastric adenocarcinomas based on genome-wide DNA copy number aberrations. This is in line with previous studies that investigated other molecular characteristics of these tumor entities. For example, the DNA hypermethylation patterns of a selected panel of genes also indicate such an association. 37 Other studies have focused on similarities between colorectal and small bowel adenocarcinomas alone. These studies indicate that genes mutated in colorectal cancer i.e. SMAD4, APC, KRAS and -catenin were also detected in small bowel adenocarcinomas although at different frequencies. 32, 38 Methylation and mutation of the APC gene, which plays a key role in the initiation of colorectal neoplasia, were detected in both colorectal and small bowel adenocarcinomas, although less frequently in the latter. This indicates that APC may not be pivotal for the initiation of small bowel adenocarcinomas.
14 The resulting small bowel and colorectal adenocarcinoma copy number alterations, which occur at a later stage of progression, still show high similarities, likewise the DNA hypermethylation.
In addition, small bowel adenocarcinomas more often show colorectal cancer characteristic cytokeratin protein staining patterns with CK20-positive and CK7-negative. 39, 40 Under the assumption that tumor biology drives phenotypic characteristics, including drug sensitivity, mutation, methylation and our aCGH data would all support treatment of MSS small bowel adenocarcinoma according to a colorectal cancer regimen.
Patients with advanced colorectal cancer bene t from 5-uorouracil based chemotherapy in combination with platinum compounds or irinotecan. 41 Several retrospective small bowel adenocarcinoma studies also demonstrate a survival bene t with such regimens. 4, 42, 43 In addition, one of the few small bowel adenocarcinoma prospective phase II clinical trials treating patients with capecitabine in combination with oxaliplatin, showed a signi cant increase in overall survival. 44 In this context it appears reasonable to assume that targeted agents like bevacizumab or cetuximab, could also be considered for systemic treatment of KRAS wild-type small bowel adenocarcinomas, since they are also bene cial for metastatic colorectal cancer. 40, 45 As Galsky et al. 46 however point out, similar targets in different tumor types may differ in their behaviour as a result of up-and downstream signalling pathways of the therapeutic targets. The genome wide copy number signature similarities between small bowel and colorectal cancers, may suggest that are also more similarities with up and downstream pathways.
Not all entities cluster entirely apart from each other; ve small bowel adenocarcinomas clustered together with gastrics. This raises the question whether small bowel adenocarcinomas with a DNA copy number aberration pro le more similar to gastric cancer originate from the duodenum, and should be treated like gastric cancer. However, only one of those ve small bowel adenocarcinomas originated from duodenum making a relationship between DNA copy number pro le and location within the small bowel unlikely. Similarly no signi cant relation was found with TNM status (supplementary Table1) or ampli cations. We speci cally looked at the ampli cation of ERBB2, known to occur frequently in gastric cancer and the target of Trastuzumab. 47 In our dataset in 4 gastric and 1 small bowel adenocarcimas ERBB2 was ampli ed. Those samples do not cluster together. One of the gastrics and the small intestinal adenocarcnimas cluster with the colorectal cancers. Subtypes of colorectal and gastric adenocarcinomas that have previously been characterized by classical pathological features such as cardia and rectum do not cluster separately based on copy number pro les, neither they in uence the clustering of the small bowel either with colorectal or gastric adenocarcinomas.
Small bowel adenocarcinoma is a very rare disease, in contrast to colorectal cancer, and several explanations for the low incidence of small bowel adenocarcinomas have been proposed including rapid turnover of small intestinal cells, lower exposure to carcinogenic components because of rapid transit time, lack of bacterial degradation and relatively dilute alkaline environment and higher activity of detoxifying enzymes like glutathione S-transferase. 48 Interestingly, the substantial difference in incidence between small bowel and colorectal adenocarcinomas is not re ected in different DNA copy number patterns observed in these two tumor types.
In this study we measure chromosomal aberrations and therefore included MSS tumors only. MSI tumors are chromosomally more stable and characterized by loss of DNA mismatch repair 19 which cannot be measured by aCGH. MSI tumors were thus excluded since we study relationships based on copy number here.
In summary, we show that genome-wide copy number pro les of most small bowel adenocarcinomas overlap primarily with colorectal adenocarcinomas. Despite limited evidence for predictive copy number pro les in general, the molecular similarities of this limited set of small bowel adenocarcinomas with colorectal cancers indicate that more patients would bene t from the colorectal speci c drug regimen rather than from a gastric speci c regimen. These similarities might also provide a further rationale for the exploration of "colorectal cancer type" drug regimens for systemic treatment of MSS small bowel adenocarcinomas. 4, 14, 48 Notwithstanding, the fact that this is the only small bowel adenocarcinoma aCGH dataset we know of, validation is still necessary to reinforce these ndings.
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SUPPLEMENTAL MATERIALS AND METHODS
Cross-platform calibration
Raw copy number ratios were reanalyzed using the original feature extraction les.
BAC and 30K oligonucleotide arrays of small bowel and gastric adenocarcinomas were The R package CGHcall 6 was used to preprocess and normalize the data. Cellularity was set to "0.7" since all samples contained 70% or more tumors cells, and normalization to "mode". For segmentation, the R package DNAcopy 7 was used; segmented log 2 ratios were renormalized by median normalization. Normalization and segmentation steps were performed separately per platform and tumor site. To allow comparisons between platforms, log 2 ratio's of all samples were re-sampled to 2000 positions equally spread over the genome, effectively 1.5Mb spatial resolution as previously described 8 . As the de ection of a copy number aberration is lower for the oligonucleotide array than for the BAC arrays 9 , all samples were calibrated to the BAC platform using results from the six samples run on both platforms. The difference in de ection between the two different platforms was determined empirically by multiplying the segmented and re-sampled oligonucleotide data by numbers from 0.5 to 2.5 in steps of 0.01 and calculating the distance in the results between the two platforms. This distance was calculated by taking the median of the differences from the 2000 data points per sample and the mean of the medians of the 6 samples for each step. The lowest distance was achieved for calibration number, n = 1.78, which is in concordance with our previously calculated calibration number 
